---
document_datetime: 2025-12-25 12:58:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/altuvoct.html
document_name: altuvoct.html
version: success
processing_time: 0.1097498
conversion_datetime: 2025-12-27 20:48:01.189386
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Altuvoct

[RSS](/en/individual-human-medicine.xml/241779)

##### Authorised

This medicine is authorised for use in the European Union

efanesoctocog alfa Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Altuvoct](#news-on)
- [More information on Altuvoct](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Altuvoct is a medicine used to prevent and treat bleeding in adults and children with haemophilia A. Haemophilia A is an inherited bleeding disorder caused by a lack of factor VIII, a protein that helps the blood clot.

Haemophilia A is rare, and Altuvoct was designated an 'orphan medicine' (a medicine used in rare diseases) on 28 June 2019.

Altuvoct contains the active substance efanesoctocog alfa.

Expand section

Collapse section

## How is Altuvoct used?

Altuvoct can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in treating haemophilia.

Altuvoct is available as a powder and a liquid to be made into a solution and given by injection into a vein, over 1 to 10 minutes. The dose depends on the patient's body weight and whether the medicine is used to prevent or treat bleeding.

To prevent bleeding (prophylaxis), Altuvoct is given once a week. To treat active bleeding (on-demand treatment), the patient is first given a single injection of Altuvoct, followed by additional injections every 2 to 3 days if necessary. The duration of the on-demand treatment depends on the severity of the disease, the location and extent of the bleeding and the patient's health condition.

Patients or their carers may be able to administer Altuvoct themselves at home once they received appropriate training.

For more information about using Altuvoct, see the package leaflet or contact your doctor or pharmacist.

## How does Altuvoct work?

Patients with haemophilia A lack factor VIII, a protein in the body that helps the blood clot. The active substance in Altuvoct, efanesoctocog alfa, resembles and replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of the bleeding disorder. Efanesoctocog alfa was designed to remain active in the body for longer than the natural factor VIII.

## What benefits of Altuvoct have been shown in studies?

Altuvoct has been shown to be effective at preventing and treating bleeding in patients with severe haemophilia A.

In a main study involving 159 patients aged 12 years and above with severe haemophilia A, 133 patients received a weekly injection of Altuvoct to prevent bleeding (prophylaxis). After 52 weeks of treatment, patients had an average of around 0.70 bleeding episodes per year. For 77 patients, data on previous treatments were available; in this group, the average number of bleeding episodes was 0.69 with Altuvoct compared with around 3 with previous treatments. During the study, most bleeding episodes were successfully treated with a single injection of Altuvoct (on-demand treatment).

In a study involving 74 children under 12 years of age with haemophilia A, treatment with Altuvoct yielded similar results to those in older patients. Altuvoct was therefore considered effective for the treatment of haemophilia A in younger children.

Combined data from 3 studies involving 41 patients with haemophilia A who underwent major surgery showed that Altuvoct is effective at preventing bleeding episodes during and after surgery.

## What are the risks associated with Altuvoct?

For the full list of side effects and restrictions with Altuvoct, see the package leaflet.

The most common side effects with Altuvoct (which may affect more than 1 in 10 people) include headache and joint pain. Other side effects with Altuvoct (which may affect up to 1 in 10 people) include vomiting, eczema (itchy, red and dry skin), rash, urticaria (itchy rash), pain in the extremities (arms and legs), back pain and fever.

As with all factor VIII medicines, patients may develop antibodies against efanesoctocog alfa, causing the medicine to stop working and resulting in a loss of bleeding control. In such cases, a specialised haemophilia centre should be contacted.

## Why is Altuvoct authorised in the EU?

The European Medicines Agency decided that Altuvoct's benefits are greater than its risks and it can be authorised for use in the EU.

Altuvoct has been shown to prevent bleeding in adults and children with haemophilia A. At the time of authorisation, most authorised factor VIII preventive treatments required an injection every 2 to 4 days. Altuvoct is given once a week which is more convenient for patients and may help patients stick to their treatment. On-demand treatment with Altuvoct is effective at treating bleeding episodes, most of which resolve after a single injection. Altuvoct is also effective at preventing bleeding in patients undergoing surgery. The side effects with Altuvoct are similar to those with other factor VIII medicines and are considered manageable. Due to how factor VIII works, there is a low risk of thromboembolic events (formation of blood clots in blood vessels) with factor VIII medicines. The company marketing Altuvoct will further investigate this risk with Altuvoct.

## What measures are being taken to ensure the safe and effective use of Altuvoct?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Altuvoct have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Altuvoct are continuously monitored. Suspected side effects reported with Altuvoct are carefully evaluated and any necessary action taken to protect patients.

## Other information about Altuvoct

Altuvoct received a marketing authorisation valid throughout the EU on 17 June 2024.

Altuvoct : EPAR - Medicine overview

Reference Number: EMA/190021/2024

English (EN) (113.94 KB - PDF)

**First published:** 12/07/2024

[View](/en/documents/overview/altuvoct-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-923)

български (BG) (137.76 KB - PDF)

**First published:**

12/07/2024

[View](/bg/documents/overview/altuvoct-epar-medicine-overview_bg.pdf)

español (ES) (113.5 KB - PDF)

**First published:**

12/07/2024

[View](/es/documents/overview/altuvoct-epar-medicine-overview_es.pdf)

čeština (CS) (135.58 KB - PDF)

**First published:**

12/07/2024

[View](/cs/documents/overview/altuvoct-epar-medicine-overview_cs.pdf)

dansk (DA) (112.16 KB - PDF)

**First published:**

12/07/2024

[View](/da/documents/overview/altuvoct-epar-medicine-overview_da.pdf)

Deutsch (DE) (117.08 KB - PDF)

**First published:**

12/07/2024

[View](/de/documents/overview/altuvoct-epar-medicine-overview_de.pdf)

eesti keel (ET) (111.16 KB - PDF)

**First published:**

12/07/2024

[View](/et/documents/overview/altuvoct-epar-medicine-overview_et.pdf)

ελληνικά (EL) (134.88 KB - PDF)

**First published:**

12/07/2024

[View](/el/documents/overview/altuvoct-epar-medicine-overview_el.pdf)

français (FR) (115.09 KB - PDF)

**First published:**

12/07/2024

[View](/fr/documents/overview/altuvoct-epar-medicine-overview_fr.pdf)

hrvatski (HR) (134 KB - PDF)

**First published:**

12/07/2024

[View](/hr/documents/overview/altuvoct-epar-medicine-overview_hr.pdf)

italiano (IT) (111.49 KB - PDF)

**First published:**

12/07/2024

[View](/it/documents/overview/altuvoct-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (143.86 KB - PDF)

**First published:**

12/07/2024

[View](/lv/documents/overview/altuvoct-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (136.71 KB - PDF)

**First published:**

12/07/2024

[View](/lt/documents/overview/altuvoct-epar-medicine-overview_lt.pdf)

magyar (HU) (135.88 KB - PDF)

**First published:**

12/07/2024

[View](/hu/documents/overview/altuvoct-epar-medicine-overview_hu.pdf)

Malti (MT) (137.99 KB - PDF)

**First published:**

12/07/2024

[View](/mt/documents/overview/altuvoct-epar-medicine-overview_mt.pdf)

Nederlands (NL) (113.07 KB - PDF)

**First published:**

12/07/2024

[View](/nl/documents/overview/altuvoct-epar-medicine-overview_nl.pdf)

polski (PL) (137.05 KB - PDF)

**First published:**

12/07/2024

[View](/pl/documents/overview/altuvoct-epar-medicine-overview_pl.pdf)

português (PT) (113.76 KB - PDF)

**First published:**

12/07/2024

[View](/pt/documents/overview/altuvoct-epar-medicine-overview_pt.pdf)

română (RO) (134.95 KB - PDF)

**First published:**

12/07/2024

[View](/ro/documents/overview/altuvoct-epar-medicine-overview_ro.pdf)

slovenčina (SK) (134.73 KB - PDF)

**First published:**

12/07/2024

[View](/sk/documents/overview/altuvoct-epar-medicine-overview_sk.pdf)

slovenščina (SL) (133.65 KB - PDF)

**First published:**

12/07/2024

[View](/sl/documents/overview/altuvoct-epar-medicine-overview_sl.pdf)

Suomi (FI) (110.95 KB - PDF)

**First published:**

12/07/2024

[View](/fi/documents/overview/altuvoct-epar-medicine-overview_fi.pdf)

svenska (SV) (111.39 KB - PDF)

**First published:**

12/07/2024

[View](/sv/documents/overview/altuvoct-epar-medicine-overview_sv.pdf)

Altuvoct : EPAR - Risk-management-plan

English (EN) (783.3 KB - PDF)

**First published:** 12/07/2024

[View](/en/documents/rmp-summary/altuvoct-epar-risk-management-plan_en.pdf)

## Product information

Altuvoct : EPAR - Product information

English (EN) (446.88 KB - PDF)

**First published:** 12/07/2024

**Last updated:** 19/12/2025

[View](/en/documents/product-information/altuvoct-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-339)

български (BG) (545.75 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/bg/documents/product-information/altuvoct-epar-product-information_bg.pdf)

español (ES) (431.57 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/es/documents/product-information/altuvoct-epar-product-information_es.pdf)

čeština (CS) (527 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/cs/documents/product-information/altuvoct-epar-product-information_cs.pdf)

dansk (DA) (425.3 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/da/documents/product-information/altuvoct-epar-product-information_da.pdf)

Deutsch (DE) (470.09 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/de/documents/product-information/altuvoct-epar-product-information_de.pdf)

eesti keel (ET) (418.54 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/et/documents/product-information/altuvoct-epar-product-information_et.pdf)

ελληνικά (EL) (577.18 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/el/documents/product-information/altuvoct-epar-product-information_el.pdf)

français (FR) (451.9 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/fr/documents/product-information/altuvoct-epar-product-information_fr.pdf)

hrvatski (HR) (504.82 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/hr/documents/product-information/altuvoct-epar-product-information_hr.pdf)

íslenska (IS) (450.77 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/is/documents/product-information/altuvoct-epar-product-information_is.pdf)

italiano (IT) (440.18 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/it/documents/product-information/altuvoct-epar-product-information_it.pdf)

latviešu valoda (LV) (522.46 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/lv/documents/product-information/altuvoct-epar-product-information_lv.pdf)

lietuvių kalba (LT) (519.5 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/lt/documents/product-information/altuvoct-epar-product-information_lt.pdf)

magyar (HU) (531.13 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/hu/documents/product-information/altuvoct-epar-product-information_hu.pdf)

Malti (MT) (565.01 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/mt/documents/product-information/altuvoct-epar-product-information_mt.pdf)

Nederlands (NL) (433.92 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/nl/documents/product-information/altuvoct-epar-product-information_nl.pdf)

norsk (NO) (419.62 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/no/documents/product-information/altuvoct-epar-product-information_no.pdf)

polski (PL) (540.19 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/pl/documents/product-information/altuvoct-epar-product-information_pl.pdf)

português (PT) (430.31 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/pt/documents/product-information/altuvoct-epar-product-information_pt.pdf)

română (RO) (526.42 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/ro/documents/product-information/altuvoct-epar-product-information_ro.pdf)

slovenčina (SK) (530.5 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/sk/documents/product-information/altuvoct-epar-product-information_sk.pdf)

slovenščina (SL) (501.13 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/sl/documents/product-information/altuvoct-epar-product-information_sl.pdf)

Suomi (FI) (430.37 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/fi/documents/product-information/altuvoct-epar-product-information_fi.pdf)

svenska (SV) (424.02 KB - PDF)

**First published:**

12/07/2024

**Last updated:**

19/12/2025

[View](/sv/documents/product-information/altuvoct-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUR/0000274459 12/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Altuvoct : EPAR - All authorised presentations

English (EN) (24.84 KB - PDF)

**First published:** 12/07/2024

[View](/en/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-294)

български (BG) (56.86 KB - PDF)

**First published:**

12/07/2024

[View](/bg/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_bg.pdf)

español (ES) (21.78 KB - PDF)

**First published:**

12/07/2024

[View](/es/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_es.pdf)

čeština (CS) (65.45 KB - PDF)

**First published:**

12/07/2024

[View](/cs/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (26.21 KB - PDF)

**First published:**

12/07/2024

[View](/da/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (30.97 KB - PDF)

**First published:**

12/07/2024

[View](/de/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (20.28 KB - PDF)

**First published:**

12/07/2024

[View](/et/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (52.38 KB - PDF)

**First published:**

12/07/2024

[View](/el/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_el.pdf)

français (FR) (27.52 KB - PDF)

**First published:**

12/07/2024

[View](/fr/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (52.58 KB - PDF)

**First published:**

12/07/2024

[View](/hr/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (25.42 KB - PDF)

**First published:**

12/07/2024

[View](/is/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_is.pdf)

italiano (IT) (26.35 KB - PDF)

**First published:**

12/07/2024

[View](/it/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (56.91 KB - PDF)

**First published:**

12/07/2024

[View](/lv/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (62.35 KB - PDF)

**First published:**

12/07/2024

[View](/lt/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (62.19 KB - PDF)

**First published:**

12/07/2024

[View](/hu/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (52.32 KB - PDF)

**First published:**

12/07/2024

[View](/mt/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (21.2 KB - PDF)

**First published:**

12/07/2024

[View](/nl/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (27.03 KB - PDF)

**First published:**

12/07/2024

[View](/no/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_no.pdf)

polski (PL) (52.21 KB - PDF)

**First published:**

12/07/2024

[View](/pl/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.21 KB - PDF)

**First published:**

12/07/2024

[View](/pt/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_pt.pdf)

română (RO) (50.93 KB - PDF)

**First published:**

12/07/2024

[View](/ro/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.65 KB - PDF)

**First published:**

12/07/2024

[View](/sk/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (41.33 KB - PDF)

**First published:**

12/07/2024

[View](/sl/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (27.24 KB - PDF)

**First published:**

12/07/2024

[View](/fi/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.56 KB - PDF)

**First published:**

12/07/2024

[View](/sv/documents/all-authorised-presentations/altuvoct-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Altuvoct Active substance Efanesoctocog alfa International non-proprietary name (INN) or common name efanesoctocog alfa Therapeutic area (MeSH) Hemophilia A Anatomical therapeutic chemical (ATC) code B02BD02

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

Altuvoct can be used for all age groups.

## Authorisation details

EMA product number EMEA/H/C/005968

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Swedish Orphan Biovitrum AB (publ)

SE-112 76

Opinion adopted 25/04/2024 Marketing authorisation issued 17/06/2024 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Altuvoct : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.55 KB - PDF)

**First published:** 19/12/2025

[View](/en/documents/procedural-steps-after/altuvoct-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Altuvoct : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (145.21 KB - PDF)

**First published:** 11/12/2024

**Last updated:** 19/12/2025

[View](/en/documents/procedural-steps-after/altuvoct-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Altuvoct-PSUSA-00011062-202502 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMADOC-1700519818-2767181

English (EN) (148.46 KB - PDF)

**First published:** 19/12/2025

[View](/en/documents/scientific-conclusion/altuvoct-psusa-00011062-202502-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Altuvoct : EPAR - Public assessment report

Adopted

Reference Number: EMA/459190/2024 Corr.1

English (EN) (5.31 MB - PDF)

**First published:** 12/07/2024

[View](/en/documents/assessment-report/altuvoct-epar-public-assessment-report_en.pdf)

Altuvoct : Orphan maintenance assessment report

Reference Number: EMA/OD/0000160184

English (EN) (752.6 KB - PDF)

**First published:** 12/07/2024

[View](/en/documents/orphan-maintenance-report/altuvoct-orphan-maintenance-assessment-report_en.pdf)

CHMP summary of positive opinion for Altuvoct

Adopted

Reference Number: EMA/167452/2024

English (EN) (121.13 KB - PDF)

**First published:** 26/04/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-altuvoct_en.pdf)

#### News on Altuvoct

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2024) 26/04/2024

#### More information on Altuvoct

- [EU/3/19/2176 - orphan designation for treatment of haemophilia A](/en/medicines/human/orphan-designations/eu-3-19-2176)

**This page was last updated on** 19/12/2025

## Share this page

[Back to top](#main-content)